The Board of Eliem Therapeutics, Inc. has approved a corporate reorganization plan to conserve financial resources. As part of the reorganization, the Company will reduce its workforce by approximately 55% in the first half of 2023. In connection with this reorganization, Bob Azelby, chief executive officer will be departing the Company and the Board imminently.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.71 USD | +0.65% | +4.05% | +185.56% |
May. 15 | Eliem Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 11 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
1st Jan change | Capi. | |
---|---|---|
+185.56% | 224M | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- ELYM Stock
- News Eliem Therapeutics, Inc.
- Bob Azelby to Depart as Chief Executive Officer of Eliem Therapeutics, Inc